Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.52 |
| ▸ | JAK2 | O60674 | 5/20 | 0.44 |
| ▸ | JAK1 | P23458 | 5/20 | 0.44 |
| ▸ | JAK3 | P52333 | 5/20 | 0.44 |
| ▸ | TYK2 | P29597 | 4/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962809 | 0.85 | PDE4B (0.53) | PDE4BMAPK1 | |
| SCHEMBL5962845 | 0.82 | PDE4B (0.54) | PDE4BJAK2JAK1JAK3TYK2 | |
| SCHEMBL8342425 | 0.73 | PDE4B (0.70) | PDE4B | |
| SCHEMBL5963166 | 0.72 | PDE4B (0.54) | PDE4BJAK2JAK1JAK3TYK2 | |
| SCHEMBL4336996 | 0.72 | PDE4B (0.81) | PDE4B | |
| SCHEMBL3428110 | 0.72 | PDE4B (0.69) | PDE4BJAK2JAK1JAK3TYK2 | |
| SCHEMBL5962970 | 0.71 | PDE4B (0.64) | PDE4B | |
| SCHEMBL5962805 | 0.69 | PDE4B (0.54) | PDE4BJAK2JAK1JAK3TYK2 | |
| SCHEMBL2773376 | 0.69 | PDE4B (1.00) | PDE4BJAK1JAK3 | |
| SCHEMBL4330662 | 0.68 | PDE4B (0.72) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE5A, PDE3B, PDE4A | PDE4B 4/4885JAK2 1205/4885JAK1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.